Organizing Committee
OCM Member
CEO & Founder , Regenerative Medicine
CEO & Founder @ Regenerage Medicine , Mexico
Biography :

International speaker on Biotechnology (mRNA) and its clinical applications with "No Option" patients. Served in various capacities in private and public practices, as hospital staff physician and as an emergency health services coordinator for a variety of private and public institutions throughout Mexico. Managed a Blood Bank from 2009-2012. MD degrees at Westhill University and the National Autonomous University of Mexico and am a qualified Physician Surgeon. Diplomate in Aesthetic Medicine from the Autonomous University of Guadalajara, and I am an Advanced Fellow with the American Board of Anti-Ageing and Regenerative Medicine, a Visiting Scholar in Dermatology, at the University of North Carolina, Chapel Hill. Fellow in Stem Cell Medicine with both the American Academy of Anti-Ageing Medicine and University of South Florida.

OCM Member
Research Director at INSERM, Osteoarticular and Dental Regenerative Nanomedicine
University of Stransbourg , France
Biography :

Dr. Nadia Benkirane is Research director and head of the “ Osteoarticular and Dental regenerative Nanomedicine” laboratory, at INSERM (French National Institute for Health and Medical Research), UMR 1109, Strasbourg, France. She was leader of “Active Biomaterials and Tissue Engineering” team INSERM 977. She received her Ph.D. from University Louis Pasteur, ULP, Strasbourg, France for the work on Development of pseudopeptides as synthetic vaccines. Dr. Jessel (Benkirane) then held a postdoctoral position in collaboration with the Institut Pasteur, Paris, France, working on Immunotherapy HIV, and another postdoctoral position on the application of modified peptides as vaccines against FMDV (Plum Island Animal Disease Center, ARS, USDA, Greenport, NY 11944-0848, USA). She joined the INSERM U595 in 2002 as a post-doc, and received the diploma to direct the research (HDR) in 2004. Dr. Jessel got the permanent position (CR1) in the INSERM 595 laboratory in 2004 and Research Director (DR2) position in the INSERM 977 and head of “active Biomaterials and Tissue Engineering team from 2009 until 2012). Currently Research Director (DR1) in the INSERM UMR 1109 (Osteoarticular and Dental Regenerative Nanomedicine" and heads the team. Dr. Jessel possesses expertise in diverse fields of molecular and cellular biology, immunochemistry, tissue engineering and biomedical engineering. In the last 10 years, she focused her research on the bio-functionalization of multilayered polyelectrolyte architectures with emphasis on the use of these architectures to induce specific cellular responses and gain control over cell proliferation and differentiation. Dr. Benkirane-Jessel have 138 publications (h index: 36) with peer-reviewed publications in high impact factor journals (Proc. Nat. Acad. Sci. USA; Adv. Mater.; Adv. Funct. Mater.; Small; Nanoletters, Biomaterials, ACS Nano), 5 chapters reviews and 5 international patents, she is a regular referee for a number of scientific journals (Nature nanotechnology, Nature Materials, ACS nano, Biomaterials, Nanoletters…). She is under the contract (Interface INSERM/Clinic 2008-2013) and she got also “Prime d’Excellence Scientifique” from the INSERM, 2010-2014 and the PEDR from the INSERM on 2016 for 4 years.

OCM Member
Manager, Development & Commercialisation at CRC for Cell Therapy Manufacturing, Cell Therapy
University of Adelaide , Australia
Biography :

Manager, Development & Commercialisation TekCyte (A business unit of CTM CRC) Tony is responsible for overseeing the translation of technologies from the laboratory to pilot-scale, adding value prior to their commercialisation. He is also responsible for seeking contract research, collaborative and/or licensing opportunities for the organisation.

Research Interest :

Cell Therapy ,Therapeutic Applications

OCM Member
Chief Scientific Officer of Alira Health and Board Member and CEO of an SPV, Firefly Innovations LLC., Cell Biology ,Tissue Engineering,Molecular Biology
Massachusetts Institute of Technology , USA
Biography :

Mitchell Sanders has over 30 years of experience in cell biology, animal models and clinical product development in advanced wound care. He has produced over 12 peer-reviewed publications and 27 worldwide patents in medical device, therapeutics, and in vitro diagnostics. Mitch is an expert in clinical and translational research and is a reviewer for the Wound Healing Society (WRR), Wounds International, Tissue Engineering, CIMIT, MassVentures, MIT, WPI, Tech Sandbox, Piranha Pond, SBANE and the Venture Forum.

OCM Member
Head of analytical development for the Cell and Gene Therapy Catapult, Cell Biology ,Cell and Gene Therapy
University of Manchester , United Kingdom
Biography :

Damian Marshall is the head of analytical development for the Cell and Gene Therapy Catapult and has almost 20 years of industrial gained working for SME’s and large companies. He leads a team of ~30 scientists working with a wide range of therapy developers helping to de-risk their route to commercialisation. This is achieved through advanced product characterisation, helping companies to manage sources of variability and gain a high level of products and process knowledge. His team is also supporting the development of new adaptive manufacturing approaches by integrating technologies to allow real-time product monitoring and enable feedback control during product manufacture.

Research Interest :

Cell therapies, Drug toxicology, Cell characterisation and Nanotechnology.

OCM Member
MD at Anderson Cancer Center , Department of Immunology
University of Texas MD Anderson Cancer Center , USA
Biography :

Finished postdoctoral training at Baylor College of Medicine (Immunology) and Harvard Medical School (Translational Cancer Research),presently working at Department of Immunology at MD Anderson focusing on tumor immunology.

OCM Member
First Scientific Director of the Basic Research Department of the San Raffaele Institute, General Pharmacology
Vita-Salute San Raffaele University of Milan , Italy
Biography :

MD cum laude (1962), Assistant and then Associate Professor at the University of Milan (1965-1980), he has been post-doc in the lab of the Nobel Graduate George E. Palade at the Rockefeller University of New York (1968-1970). Professor of General Pharmacology at the University of Milan (1981-1999) and then at the Vita-Salute San Raffaele University of Milan, he is an Emeritus since November 2010.

OCM Member
Scientist at Genethon , Gene Therapy ,Neuro Science ,Toxicology
Istituto Italiano di Tecnologia , Italy
Biography :

Dr. Ronzitti is group leader at Genethon. His main interest is the development of adeno-associated virus (AAV)-based gene therapies for rare disorders. In 2013, he arrived at Genethon as a post-doc supervised by Dr. Mingozzi to develop a gene therapy approach for Crigler-Najjar, a metabolic syndrome. This approach is now being translated in the clinic and the first patient will be injected this year.

Research Interest :

Cell therapies, Drug toxicology, Cell characterisation and Nanotechnology.

OCM Member
Professor, Department of Pathology
Federal University of Minas Gerais , Brazil
Biography :

Dr. Alexander Birbrair started his scientific career from B.S. in Biomedical Sciences from Universidade Estadual de Santa Cruz, UESC, Ilheus, Brazil. He completed his Ph.D. in Neurosciences Program, particularly in the field of Stem Cell Biology, from Wake Forest School of Medicine, Winston-Salem, NC, USA. Dr. Birbrair received his Post-Doctoral Degree from Albert Einstein College of Medicine, Bronx, NY, USA in Stem Cell Biology and joined as a Professor at Department of Pathology, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil in 2016. He is a recipient of several notable awards and honours, which includes, Gordon A. Melson Outstanding Doctoral Student Award for 2015 and Editor's choice Award in Journal of Gerontology Biological Sciences Volume 69 Issue 12 December 2014 for the manuscript “Human Slow Troponin T (TNNT1) Pre-mRNA Alternative Splicing is An Indicator of Skeletal Muscle Response to Resistance Exercise in Older Adults.” by Zhang T, Choi SJ, Wang ZM, Birbrair A, Messi ML, Jin J-P, Marsh AP, Nicklas B, and Delbono O. He is an active member of American Heart Association, Western NC Chapter of the Society for Neuroscience and International Society for Stem Cell Research with more than 30 publications in peer-reviewed journals and serves as an ad hoc reviewer for 14 Journals related to pathology and stem cell biology.

Research Interest :

Cell therapies, Drug toxicology, Cell characterisation and Nanotechnology.

Allied Academies Global Conference Directory

Mail us at

Program enquiry
genetherapy@alliedscholars.com
General enquiry
celltherapy@alliedscholars.net
Sponsorship Opportunity
genetherapy@alliedscholars.com
More details about sponsorship:sponsors@alliedacademies.com

Terms and Conditions

Responsibility

The organizers holds no responsibilities or liabilities of the personal articles of attendees at the venue against any kind of theft, lost, damage, due to any reason whatsoever. Delegates are entirely responsible for the safety of their own belongings.

 

Insurance

No insurance, of any kind, is included along with the registration in any of the events of the organization.

 

Transportation

Please note that transportation and parking is the responsibility of the registrant, Allied Academies will not be liable for any actions howsoever related to transportation and parking.

 

Press/Media

Press permission must be obtained from Allied Academies Conference Organizing Committee prior to the event. The press will not quote speakers or delegates unless they have obtained their approval in writing. The Allied Academies is an objective third-party non profit organization and this conference is not associated with any commercial meeting company.

 

Requesting an Invitation Letter

For security purposes, letter of invitation will be sent only to those individuals who had registered for the conference after payment of complete registration fee. Once registration is complete, please contact cellgenetherapy@alliedconferences.org to request for a personalized letter of invitation, if not received until one month before the scheduled date of event.

All the bank charges applicable during refund will be deducted from the account of participant.

 

Cancellation Policy

All cancellations or modifications of registration must be made in writing to finance@alliedacademies.com

 

Postponement of event

If, due to any reason, Allied academies postpone an event and the participant is unable or unwilling to attend the conference on rescheduled dates, he/she is eligible for a credit of 100% of the registration fee paid. This credit shall only be used for another event organized by Allied academies within period of one year from the date of rescheduling.

 

Transfer of registration

All registrations, after payment of complete registration fee, are transferable to other persons from the same organization, if in case the person is unable to attend the event. Request for transfer of registration must be made by the registered person in writing to contact@alliedacademies.com . Details must include the full name of replaced new registrant, their title, contact phone number and email address. All other registration details will be assigned to the new person unless otherwise specified.

Registration can be transferred to one conference to another conference of Allied academies if the person is unable to attend one of conferences.

However, Registration cannot be transferred if intimated within 14 days of respective conference.

The transferred registrations will not be eligible for Refund.

This cancellation policy was last updated on April 04, 2015.

 

 

Visa Information

Keeping in view of increased security measures, we would like to request all the participants to apply for Visa as soon as possible.

Allied academies will not directly contact embassies and consulates on behalf of visa applicants. All delegates or invitees should apply for Business Visa only.

Important note for failed visa applications: Visa issues are not covered under the cancellation policy of Allied academies, including the inability to obtain a visa.

 

Refund Policy:

If the registrant is unable to attend, and is not in a position to transfer his/her participation to another person or event, then the following refund policies apply:

Keeping in view of advance payments towards Venue, Printing, Shipping, Hotels and other overhead charges, following Refund Policy Orders are available:

  • Before 60 days of the conference: Eligible for Full Refund after deduction of $100 towards service Fee.
  • Within 60-30 days of Conference: Eligible for 50% of payment Refund
  • Within 30 days of Conference: Not eligible for Refund
  • E-Poster Payments will not be refunded.

Accommodation Cancellation Policy:

Accommodation Service Providers (Hotels) have their own cancellation policies which are applicable when cancellations are made less than 30 days prior to arrival. If in case the registrant wishes to cancel or amend the accommodation, he/ she is expected to inform the organizing authorities on a prior basis. Allied academies will advise the registrant to ensure complete awareness about the cancellation policy of your accommodation provider, prior to cancellation or modification of their booking.

 

 

Authorization Policy

Copyright © 2018-2019 Allied Academies, All Rights Reserved.